"BI-RADS 3 is an intermediate category in the breast imaging reporting and data system. A finding placed in this category is considered probably benign, with a risk of malignancy of > 0% and ≤ 2%4."
"BI-RADS 3 is an intermediate category in the breast imaging reporting and data system. A finding placed in this category is considered probably benign, with a risk of malignancy of > 0% and ≤ 2%4."
"BI-RADS 3 should not be utilised in the screening setting. It should be reserved for the diagnostic setting, such as when patients are recalled from screening for additional views (ie, following BI-RADS 0) or when patients present with a palpable lump."
"BI-RADS 3 should not be utilised in the screening setting. It should be reserved for the diagnostic setting, such as when patients are recalled from screening for additional views (ie, following BI-RADS 0) or when patients present with a palpable lump."
"The BI-RADS Atlas, fifth edition, contains three mammographic findings that should be categorised as BI-RADS 3 4,6:"
"The BI-RADS Atlas, fifth edition, contains three mammographic findings that should be categorised as BI-RADS 3 4,6:"
"The following sonographic findings may be categorised as BI-RADS 3 6:"
"microlobulated or oval mass composed of clustered microcysts (although BI-RADS 2 may be appropriate if the appearance is classic 7)"
"BI-RADS 3 carries a management recommendation of short-term follow-up. The recommendation should be for the modality or modalities that best demonstrated the initial finding. While follow-up protocols differ across practices, a common schedule is at 6, 12, and 24 months. Once stability is documented for at least two, and at most three years, the finding can be downgraded to BI-RADS 2 (benign). If the finding develops suspicious features such as growth, non-circumscribed margins, or suspicious calcification morphology, then a BI-RADS 4 or BI-RADS 5 classification should be considered."
"BI-RADS 3 carries a management recommendation of short-term follow-up. The recommendation should be for the modality or modalities that best demonstrated the initial finding. While follow-up protocols differ across practices, a common schedule is at 6, 12, and 24 months. Once stability is documented for at least two, and at most three years, the finding can be downgraded to BI-RADS 2 (benign). If the finding develops suspicious features such as growth, non-circumscribed margins, or suspicious calcification morphology, then a BI-RADS 4 or BI-RADS 5 classification should be considered."
"BI-RADS 3 carries a management recommendation of short-term follow-up. The recommendation should be for the modality or modalities that best demonstrated the initial finding. While follow-up protocols differ across practices, a common schedule is at 6, 12, and 24 months. Once stability is documented for at least two, and at most three years, the finding can be downgraded to BI-RADS 2 (benign). If the finding develops suspicious features such as growth, non-circumscribed margins, or suspicious calcification morphology, then a BI-RADS 4 or BI-RADS 5 classification should be considered."
"BI-RADS 3 carries a management recommendation of short-term follow-up. The recommendation should be for the modality or modalities that best demonstrated the initial finding. While follow-up protocols differ across practices, a common schedule is at 6, 12, and 24 months. Once stability is documented for at least two, and at most three years, the finding can be downgraded to BI-RADS 2 (benign). If the finding develops suspicious features such as growth, non-circumscribed margins, or suspicious calcification morphology, then a BI-RADS 4 or BI-RADS 5 classification should be considered."
"circumscribed, round or oval mass without calcification"